RT info:eu-repo/semantics/article
T1 Can the Cytokine Profile According to ABO Blood Groups Be Related to Worse Outcome in COVID-19 Patients? Yes, They Can
A1 Tamayo Velasco, Álvaro
A1 Peñarrubia Ponce, María Jesús
A1 Álvarez González, Francisco Javier
A1 Gonzalo Benito, Hugo
A1 Fuente, Ignacio de la
A1 Pérez González, Sonia
A1 Rico, Lucía
A1 Jiménez García, María Teresa
A1 Sánchez Rodríguez, Alba
A1 Hijas Villaizán, Milagros
A1 Martín Fernández, Marta
A1 Dueñas, Carlos
A1 Gómez Sánchez, Esther
A1 Heredia Rodríguez, María
A1 Gorgojo Galindo, Óscar
A1 Fernández Martínez, Itziar
A1 Río Sola, María Lourdes del
A1 Carnicero Frutos, Irene
A1 Muñoz Moreno, María Fe
A1 Tamayo Gómez, Eduardo
A1 Bernardo Ordiz, David
A1 Martínez de Paz, Pedro José
K1 COVID-19 (Enfermedad)
K1 Cytokines
K1 Citoquinas
K1 Mortality
K1 Mortalidad
AB Severe status of coronavirus disease 2019 (COVID-19) is extremely associated to cytokine release. Moreover, it has been suggested that blood group is also associated with the prevalence and severity of this disease. However, the relationship between the cytokine profile and blood group remains unclear in COVID-19 patients. In this sense, we prospectively recruited 108 COVID-19 patients between March and April 2020 and divided according to ABO blood group. For the analysis of 45 cytokines, plasma samples were collected in the time of admission to hospital ward or intensive care unit and at the sixth day after hospital admission. The results show that there was a risk of more than two times lower of mechanical ventilation or death in patients with blood group O (log rank: p = 0.042). At first time, all statistically significant cytokine levels, except from hepatocyte growth factor, were higher in O blood group patients meanwhile the second time showed a significant drop, between 20% and 40%. In contrast, A/B/AB group presented a maintenance of cytokine levels during time. Hepatocyte growth factor showed a significant association with intubation or mortality risk in non-O blood group patients (OR: 4.229, 95% CI (2.064–8.665), p < 0.001) and also was the only one bad prognosis biomarker in O blood group patients (OR: 8.852, 95% CI (1.540–50.878), p = 0.015). Therefore, higher cytokine levels in O blood group are associated with a better outcome than A/B/AB group in COVID-19 patients.
PB Frontiers
SN 1664-3224
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/51578
UL https://uvadoc.uva.es/handle/10324/51578
LA eng
NO Frontiers in Immunology, 2021, vol. 12, 726283
NO Producción Científica
DS UVaDOC
RD 19-nov-2024